Retroscreen Virology Limited, the global leader in anti-viral research, clinical trials and experimental challenge studies, is pleased to announce that it’s CEO, Dr Robert Lambkin-Williams, will be a key speaker at the BIT’s 1st World Congress of Virus and Infection 2010.

The conference, which will be held on July 31st to August 3rd 2010 at the Busan Exhibition and Convention Centre, Korea, will have 3 parallel symposiums: 1st World Congress of Virus and Infections, 1st Annual Inaugurate Symposium of Hepatitis Virus and 3rd Annual World Summit of Antivirals.  WCVI 2010 will pave the way for hepatitis virus’ and enlarge its involvement in animal and plant antivirals.

For Further information:

Notes to Editors

About Retroscreen Virology Ltd
RVL is unique in being the only contract research organisation (CRO) in the world that offers experimental infection studies with viruses in human volunteers under quarantine conditions (human challenge studies). Founded in 1989 by John Oxford, Professor of Virology, University of London, the Company, a global leader in anti-viral research, designs and coordinates clinical trials for global pharmaceutical and biotechnology companies that are developing novel antiviral drugs and vaccines. To date, RVL has conducted over 30 such quarantines, infecting over 700 volunteers. Experimental challenge studies can help reduce both the cost and the duration of drug development by accelerating the selection of dose and dosing regimes for later licensing studies. RVL is ISO9001 accredited and is partnered with a number of leading UK universities, including Queen Mary, University of London.

Clinical trials: RVL offers a comprehensive service from protocol and case report form design through to effecting and co-ordinating the study. The Company is especially renowned for its unique experimental challenge studies, conducted under strict quarantine conditions at its UK Flu Camps (see www.flucamp.com).

Analytical Services and Clinical Trial Support: RVL has invested in the development and optimisation of in vitro antiviral assay techniques to support clinical trials. The Company specialises in assays for respiratory viruses such as influenza, RSV, and rhinovirus (the common cold), as well as gastrointestinal viruses among others.

ENDS